ライフサイエンスコーパス: aminonucleoside

1 ty to glomerular damage induced by puromycin aminonucleoside.

2 nduced in rats by the injection of puromycin aminonucleoside.

3 bstitution with dimethylamine gave puromycin aminonucleoside [9-(3-amino-3-deoxy-beta-D-ribofuranosyl

4 oheximide, emetine, puromycin, and puromycin aminonucleoside, a negative analog, were evaluated for t

5 t of differentiated podocytes with puromycin aminonucleoside, an agent that causes foot process effac

6 einuria and hypoalbuminemia in the puromycin aminonucleoside and adriamycin rat models of nephrotic s

7 y was induced in C57BL/6 mice with puromycin aminonucleoside, and the selective A(2A)R agonist ATL313

8 These results demonstrate the effects of 3'-aminonucleoside anomeric configuration on sugar puckerin

9 2'-aminonucleosides are commonly used as sites of post-synt

10 The alpha-3'-aminonucleoside building blocks used for oligonucleotide

11 lar injury, because treatment with puromycin aminonucleoside enhanced proteinuria in TG mice compared

12 awley rats by an i.v. injection of puromycin aminonucleoside in saline; seven control rats received s

13 on of OX-7 monoclonal antibody and puromycin aminonucleoside in which 10(7) SPIO- and DiI-labeled MSC

14 efore or after sublethal injury by puromycin aminonucleoside, in the presence or absence of angiotens

15 athepsin L are protected from cell puromycin aminonucleoside-induced cell detachment.

16 nderscored by the observation that puromycin aminonucleoside-induced cell migration was slowed down i

17 cantly protected podocytes against puromycin aminonucleoside-induced injury (designed to mimic nephro

18 ctin cytoskeleton that accompanied puromycin aminonucleoside-induced injury in vitro.

19 reduced peak proteinuria caused by puromycin aminonucleoside-induced nephropathy.

20 Rats with puromycin-aminonucleoside-induced nephrotic proteinuria displayed

21 ritoneum permeability of rats with puromycin aminonucleoside-induced nephrotic syndrome.

22 lpha(3) integrin protected against puromycin aminonucleoside-induced podocyte detachment.

23 We found that puromycin aminonucleoside-induced proteinuria in rats was signific

24 rization of EPZ-5676, a potent and selective aminonucleoside inhibitor of DOT1L histone methyltransfe

25 y increased GEN sprouting, whereas puromycin aminonucleoside-injured podocyte supernatant decreased t

26 Notably, in the puromycin aminonucleoside model, hyperfibrinogenemia and antithrom

27 In puromycin aminonucleoside nephrosis (PAN), GIV expression increase

28 ere, we show that the induction of puromycin aminonucleoside nephrosis involves podocyte migration co

29 Furthermore, the rat puromycin aminonucleoside nephrosis model, previously suspected of

30 evels of proteinuria were induced (using the aminonucleoside of puromycin) in normocomplementemic and

31 in humans, in animals treated with puromycin aminonucleoside, or in humans or animals with mutations

32 the passive Heymann nephritis and puromycin aminonucleoside (PA) nephrosis rat models of podocyte in

33 docytes in culture were exposed to puromycin aminonucleoside (PA) to induce apoptosis.

34 on and phosphorylation of hsp27 in puromycin aminonucleoside (PAN) -induced experimental NS.

35 n podocytes from rats treated with puromycin aminonucleoside (PAN) and from patients with focal segme

36 a in a rat model of MCD induced by puromycin aminonucleoside (PAN) and in vitro cultured mouse podocy

37 ts of this mutation in response to puromycin aminonucleoside (PAN) nephrosis.

38 and 21 days after the induction of puromycin aminonucleoside (PAN) nephrosis.

39 y rats by intravenous injection of puromycin aminonucleoside (PAN), whereas control rats received phy

40 function and structure in chronic puromycin aminonucleoside (PAN)-induced nephropathy in rats were e

41 Puromycin aminonucleoside (PAN)-induced nephrosis is a well-descri

42 a glomerular injury-inducing agent puromycin aminonucleoside (PAN).

43 The inactive agent, puromycin aminonucleoside, produced marked repression of the PB-in

44 eraction is disrupted in GECs from puromycin aminonucleoside-, protamine sulfate-, or sialidase-treat

45 foot process effacement using the puromycin aminonucleoside rat model resulted in significant increa

46 The peritoneum of puromycin aminonucleoside rats displayed an increase in the water

47 n of receptor-operated channels in puromycin aminonucleoside-treated podocytes leads to increased cal

48 WT1 heterozygous knockout mice and puromycin aminonucleoside-treated rats).

49 Puromycin aminonucleoside treatment up-regulates cathepsin L expre

50 Puromycin aminonucleoside was without effect on these pathways, de

51 The base-protected alpha-5'-O-DMT-3'-aminonucleosides were assembled into dimers and oligonuc